Sandoz shares jump on improved guidance

 Swiss drugmaker Sandoz shares jumped after the company bumped up its revenue guidance thanks to growth in its biosimilar product range.

Sandoz stock rose 6.4%, or 4.18 euros, to 69.80 euros in early afternoon European trade.

The launch of generic treatments in the U.S. for psoriasis, osteoporosis and multiple sclerosis helped to boost 2025 revenue. Net sales grew by 5% at a constant exchange rate to $11.09 billion, broadly in line with analyst expectations.

New guidance issued by the company forecast sales growth in the mid-to-high single digits thanks to growth in biosimilars—biological drugs that replicate a branded equivalent.

The guidance points to sales growth ahead of consensus expectations of 6.8%, Jefferies analysts said.

Meanwhile, margins should grow by 1%, the company said, ahead of consensus forecast of 0.8%.

https://www.msn.com/en-us/money/companies/sandoz-shares-jump-on-improved-guidance/ar-AA1X366s